CoChat

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date

Open access
Jia, Xiaoming, Koh, Stephanie, Al Rifai, Mahmoud, Blumenthal, Roger S, Virani, Salim S · 2020 · Vascular Health and Risk Management

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

Icosapent ethyl is a highly purified formulation of eicosapentaenoic acid, a type of omega-3 fatty acid contained in fish oil. While omega-3 fatty acids have long been thought to have cardioprotective benefits, the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) has helped to establish icosapent ethyl as an evidence-based therapy for risk reduction of atherosclerotic cardiovascular disease (ASCVD). REDUCE-IT, however, was by no means an overnight success story. Close examination of the evidence shows that the trial was a culmination of many lessons learned from previous studies. The purpose of this manuscript is to review contemporary evidence of icosapent ethyl in ASCVD risk reduction and the clinical implication of this promising therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/vhrm.s210149

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. [58]Institute for Clinical and Economic Review. Additive Therapies for Cardiovascular Disease: Effectiveness and Value; 2019 Available from: https://icer-review.org/wp-content/uploads/2019/02/ICER_CVD_Draft_Evidence_Report_072419.pdf. Accessed December 2, 2019.
  2. [60]UMIN-CTR Clinical Trial. Randomized trial for evaluation in secondary prevention efficacy of combination therapy — statin and eicosapentaenoic acid UMIN000012069; 2018. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014051. Accessed November 22, 2019. 38873793

Cited by

See all 14

Metadata

Authors
Jia, X., Koh, S., Al Rifai, M., Blumenthal, R. S., & Virani, S. S.
Affiliations
  • Baylor College of Medicine (US)
  • Johns Hopkins University (US)
  • Michael E. DeBakey VA Medical Center (US)
Corresponding author
Virani, Salim S
Venue
Vascular Health and Risk Management
Published
2020-01
Volume
Volume 16
Pages
1-10
ISSN
  • 1176-6344 (ISSN-L)
  • 1178-2048
OpenAlex
W3000366026
Cited by
14
References
69
Citations by year
2024: 3 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 5
FWCI
0.34
Type
journal article
Language
en
Open access
Locations
  • Vascular Health and Risk Management (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
  • eCommons - AKU (Aga Khan University) (submittedVersion, cc-by-nc)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
Keywords
icosapent ethyl, eicosapentaenoic acid, omega-3 fatty acids, fish oil, atherosclerotic cardiovascular disease, cardiovascular risk reduction, REDUCE-IT trial, cardioprotection
MeSH terms
Animals, Cardiovascular Diseases, Humans, Risk Factors, Eicosapentaenoic Acid, Risk Assessment, Evidence-Based Medicine, Dietary Supplements, Protective Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.